Drug Profile
S-Etifoxine
Alternative Names: (S)-EtifoxineLatest Information Update: 20 Sep 2023
Price :
$50
*
At a glance
- Originator Anvyl
- Class
- Mechanism of Action TSPO protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 20 Sep 2023 Discontinued - Preclinical for Neuropathic pain in USA (unspecified route)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Neuropathic-pain in USA
- 28 Sep 2016 Anvyl has patent protection for S-etifoxine (before September 2016)